Published in Blood on May 15, 1994
Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med (1996) 3.30
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol (1989) 2.12
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost (2003) 2.12
Uveitis masquerade syndromes. Ophthalmology (2001) 2.02
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 2.01
Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol (1990) 2.00
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Functional studies on lymphocytes in adult human bone marrow. II. Isolated surface IgM-positive cells. J Immunol (1979) 1.70
Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med (1987) 1.63
Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. Am J Dis Child (1993) 1.61
Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology (2000) 1.60
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis (1985) 1.45
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine (1997) 1.44
[Withdrawing the use of acetylsalicyclic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd (2003) 1.42
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost (2007) 1.42
How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis (2001) 1.41
High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol (1992) 1.41
Three families with polyneuropathy associated with monoclonal gammopathy. Arch Neurol (2000) 1.39
Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med (1995) 1.39
[Two patients with hypereosinophilic syndrome]. Ned Tijdschr Geneeskd (2006) 1.39
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia (2003) 1.37
A gene expression signature for high-risk multiple myeloma. Leukemia (2012) 1.36
Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol (2000) 1.32
Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med (1981) 1.29
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28
Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation (2003) 1.28
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2002) 1.22
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet (1998) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
Sporadic late-onset nemaline myopathy effectively treated by melphalan and stem cell transplant. Neurology (2008) 1.20
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant (2003) 1.16
Specific lymphocyte stimulation by purified, heat-inactivated hepatitis-B antigen. Br Med J (1973) 1.16
Lymphocyte 5'-nucleotidase in primary hypogammaglobulinaemia and cord blood. Clin Exp Immunol (1980) 1.14
Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection. J Clin Microbiol (1990) 1.14
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia (2011) 1.13
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
The human immune response to alpha-haemocyanin of Helix pomatia. Acta Med Scand (1973) 1.11
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
[Neurological presentation of non-Hodgkin lymphoma: a diagnostic problem]. Ned Tijdschr Geneeskd (1997) 1.10
Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man. Clin Exp Immunol (1978) 1.10
Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant (2000) 1.09
Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology (1990) 1.08
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J (2011) 1.07
Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation? Lancet (1984) 1.07
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol (1998) 1.05
Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol (1992) 1.04
Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol (1989) 1.04
Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics (1989) 1.03
Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood (1997) 1.03
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Detection of cytomegalovirus (CMV) in granulocytes by polymerase chain reaction compared with the CMV antigen test. J Clin Microbiol (1992) 1.01
The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia (2002) 1.01
Allogeneic bone marrow transplantation can restore CD4+ T-lymphocyte count and immune function in idiopathic CD4+ T-lymphocytopenia. Bone Marrow Transplant (1996) 1.00
Associated expression of CD1 antigen and Fc receptor for IgE on epidermal Langerhans cells from patients with atopic dermatitis. Clin Exp Immunol (1988) 1.00
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
MicroRNA signatures characterize multiple myeloma patients. Leukemia (2011) 1.00
Immunoglobulin and complement inclusions in peripheral blood polymorphonuclear leucocytes of patients with bronchial carcinoma. Thorax (1977) 0.99
Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol (1998) 0.99
The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol (2002) 0.99
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant (2008) 0.98
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 0.98
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation (1993) 0.97
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia (2003) 0.97
Responses of platelets to strains of streptococcus sanguis: findings in healthy subjects, Bernard-Soulier, Glanzmann's, and collagen-unresponsive patients. Thromb Haemost (1987) 0.97
Absence of ligands bound to glycoprotein IIB-IIIA on the exposed surface of a thrombus may limit thrombus growth in flowing blood. J Clin Invest (1994) 0.96
Functional studies on lymphocytes in adult human bone marrow. I. Immunoglobulin production in vitro after fractionation on a sucrose gradient and T/non-T cell separation. J Immunol (1979) 0.95
Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol (1997) 0.95
Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia (2005) 0.95
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia (2011) 0.95
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol (2003) 0.95